Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation (NIBS) method, which modulates the membrane potential of neurons in the cerebral cortex by a low-intensity direct current. tDCS is a low-cost technique with minimal adverse effects and easy application. This neurostimulation method has a promising future to improve pain therapy, treatment of neuropsychiatric disorders, and physical rehabilitation.
Introduction
Non-invasive brain stimulation (NIBS), such as transcranial magnetic stimulation (TMS) and tDCS, is emerging as a therapeutic option for various conditions, such as neuropsychiatric disorders . It is a low-cost technique, with easy application and practically no adverse effects.
However, the use of long-term tDCS becomes impracticable for many patients with chronic disease. When we analyze the current evidence about tDCS, we can observe that most protocols used fewer than 20 sessions and also, the treatment was administered in a specialized center 6 . Nonetheless, it is a frequent complaint of patients that they spend time and money to go the center.
In the real world, there are several everyday difficulties of patients receiving this kind of therapy because frequently they are suffering from refractory pain and/or they have severe psychiatric or neurological disorders. Many of them have difficulties walking or are wheelchair users. An ideal device should guarantee consecutive sessions for long-term therapies as well as be able to run more extensive clinical trials with larger sample sizes. Furthermore, the device should have a block system to guarantee the dose of stimulation while avoiding any abusive or excessive use. Also, the development of a device to be used without direct supervision can test its effectiveness in different samples, either as a unique method or combined with pharmacological treatments, cognitive tasks or physical functions 11, 12 . Thus, we need to take into account that the repeated sessions are an intrinsic characteristic of this kind of treatment according to a vast set of evidence. A clinical response usually requires repeated sessions of stimulation during extended periods 5, 13, 14 . In this context, there exists a gap to develop a portable tDCS device for home use, at the lowest cost, that is easy to handle and guarantees the safety and benefits observed in studies under direct supervision at care centers.
Presently the most advanced system available to use tDCS at home requires remote assistance, which is a considerable barrier to large scale treatment, especially in the long-term. In fact, in real life, it is not feasible to maintain a long-term intervention if the patient and the operator controlling the device remotely need to be connected to a video conferencing platform simultaneously. The remote support is a barrier to maintain the treatment because both the patients and the operator controlling the remote need to be available at a pre-determined time of day for the treatment to occur. This is not practical, and it withdraws the patient's autonomy to decide what is the best moment for the treatment session according to their daily life routine 15, 16 . Taking this into account, a tDCS device to be used at home should be practical and friendly for users. The tDCS device presented in this study is simple and with a short training can give the ability for the participants' to use the apparatus at home.
An essential characteristic of our device is that it was designed for home use. For this reason, we include a block system to avoid any indiscriminate use. Thus, an untrained individual can use the device, and the technique can be reproduced across studies to make comparison of results possible between clinical trials 11, 15, 17 . Aiming to reduce difficulties related to long-term treatment, we developed a protocol using a home-based tDCS device; here we present a protocol for a safe and straightforward portable tDCS device, preventing its improper use 16 . We validated this protocol of the home-based tDCS in both healthy subjects and fibromyalgia patients, as well as showed its feasibility as attested by electrophysiological parameters (i.e., motor evoked potential), and clinical measures.
We included healthy subjects and fibromyalgia patients in this study. Fibromyalgia is a syndrome that comprises chronic widespread musculoskeletal pain accompanied by other symptoms such as depressive symptoms, fatigue, sleep disturbance, and morning stiffness. Many patients experience continued symptoms despite initial pharmacological treatment at the maximum tolerated dose. Hence, we advise studying different treatment modalities, including non-pharmacological measures such as the NIBS techniques, in this context, the home-based tDCS. tDCS is a potentially viable option in the treatment of chronic pain, as demonstrated in several studies 4, 6, 7 . The development of a home-based tDCS allows the creation of long-term clinical trials, and a better understanding of the cumulative effect of tDCS for chronic disorders (i.e., chronic pain, depression, rehabilitation after stroke, etc.).
Despite the fact that tDCS use has increased and there is a reasonably large body of research on its effects and impact across a range of clinical conditions, a surprisingly limited amount of research has been conducted on developing a device that can be feasibly and securely used at home. Therefore, the objective of this study was to evaluate the feasibility of the tDCS device for home use (monitoring of adherence and contact impedance) in healthy subjects and fibromyalgia patients.
Protocol
This study was approved by the institutional ethics committee at the HCPA and obtained written informed consent from all subjects. Details of the study with a sample of healthy subjects and fibromyalgia patients are in Figure 1. The device has dimensions of 110 mm x 75 mm and a weight of 165 g. Consumption while in use is 20 mA and 10 µA on stand-by and can only be programmed by researchers. 1. Set the device parameters: the fixed number of stimulation sessions, the minimum interval between two consecutive sessions, the intensity of the electric current, duration of stimulation, the rise and descent time of the current, and stimulation mode: active or sham.
Participant Recruitment and Screening
2. Cap/Silicone Probes/Electrodes NOTE: The cap's material is neoprene, which facilitates contact of the sponges to the scalp, keeping the sponges fixed at the stimulation site. The cap has a Velcro strap attached to the chin ensuring the cap does not move during the stimulation. 1. Choose the correct dimensions of the cap. The cap allows facilitated contact of the sponges to the scalp, keeping the sponges fixed at the stimulation site, and has three sizes: small (38 cm x 55 cm), medium (39 cm x 57.5 cm) and large (40 cm x 59 cm). 2. Put the cap on the participant and measure/mark the chosen region. 3. Remove the participant's cap and drill the cap at the desired location. Attach the electrodes and connect the silicone cannulas and filled syringes of the saline solution. Form electrodes from 35 cm 2 conductive rubber electrodes coated with a vegetable sponge and a metal piece that connects it to the silicone cannulas (Figure 2 ).
3. Protocols 1. Define a protocol for participants. For healthy subjects, use anodal stimulation over the left primary motor cortex (M1) and cathodal stimulation over the contra-lateral supra-orbital area ( Figure 3A) , 2 mA for 20 min, in a total of 10 consecutive sessions. 2. Define a protocol for patients. For fibromyalgia patients, use anodal stimulation over the left dorsolateral prefrontal cortex (DLPFC) ( Figure 3B ), 2 mA for 30 min, in five consecutive days (Monday to Friday) in a total of 60 sessions. Randomize FM patients to one of two treatments (active or sham tDCS). A researcher not involved in data collection performed the randomization and used the computer program entitled Randomization.com. NOTE: During active stimulation, there is ramp-up time of 20 s for the current to go from zero to 2 mA and a ramp-down time that also takes 20 s for the current to go from 2 mA to zero to end the stimulation. In this way, the participant does not suffer from an abrupt interruption of the current and the visualization of spots or light spots, known as phosphenes, produced from electrical or magnetic stimulation 19, 20 . The sham application has the same ramp-up and ramp-down time, but in three moments: at the beginning, in the middle (at 15 min) and at the end of the session (at 30 min), to convince the participant that they are receiving the stimulation.
Baseline Protocol Visit -tDCS Training
1. Prepare the materials for each participant: a case containing a neoprene cap, a tDCS device, a battery charger, 2 electrodes, 2 silicone cannulas attached to the electrodes, 20 syringes with 10 mL of saline and two syringes of additional physiological saline solution, and one bottle of additional physiological saline solution. 2. Hold a training session with the participant and inform them about the details of the device and the step-by-step process for self-stimulation administration. Participants should also watch an instructional video about the use of tDCS at home. 3. Training Session 1. Inspect the skin for any injury or something that contraindicates the tDCS use. 2. Place the participant in front of a mirror and separate their hair in order to reveal the area to be stimulated, according to the protocol of the study. 3. Clean the surface of the skin to remove creams, dirt or grease. 4. Put the cap on the head with the front seam between the eyebrows. The cap is to be neither tight nor loose but comfortable. 5. Connect the electrode cable to the device and turn on the equipment.
Sequence of screens
1. Turn on the device and the first screen will appear: Opening screen ( Figure 4A) . 2. Wait a few seconds and the second screen will appear: Battery status ( Figure 4B ). In the sequence, the third screen will show the date and time (Figure 4C ). 3. As the next screen is the command wear the cap, push the central button after making sure the cap is well secured (Figure 4D ). 4. Wait for the command inject saline. Make sure the saline is fed slowly to the electrodes using the already connected syringe, using 6 mL for each electrode. Press the central button after injecting the saline (Figure 4E ). 5. The sixth screen is the command to start the session. The participant must press the center button when ready to begin the stimulation (Figure 4F ). 6 . As the seventh screen shows the beginning of the stimulation, see in the display: session duration, battery charge, and two lines. The upper line shows the intensity (I), and the bottom line shows the resistance (R) (Figure 4G) . NOTE: The intensity will gradually increase until reaching 2 mA (or another defined intensity). The resistance should approximately reach the middle of this line (5 kΩ), and the investigator can configure the device to the maximum impedance limit they want. 7. Wait for the end of the stimulation, and after twenty minutes (or other stipulated time), the tDCS device powers off and stimulation ceases, saving the session data to the device software ( Figure 5 ). 
Discussion
The device presented an adequate user interface via the LCD (liquid crystal display) and was user-friendly and easy to use. Our home-based tDCS equipment proved to be suitable for long-term use since adherence was higher than 90% even when participants were instructed to perform 60 home-based sessions. This enables the reproducibility of research conditions 13, 21 necessary for the idealization and confidence in studies with this device.
It is challenging to maintain adherence when research involves consecutive sessions without intervals on weekends. This fact is one of the hypotheses raised to justify why healthy participants had slightly lower adherence than fibromyalgia patients. Also, a rationale to explain the current results may be that patients with chronic pain have the possibility of pain relief as a motivator, which does not occur in healthy subjects.
The use of home-based tDCS allows participants to choose what time of day to receive the treatment, therefore accommodating patients' schedules. Also, other research protocols comparing different times of tDCS application can be devised using this device, linking to other areas of study, such as chronobiology of pain, for example. Besides, the device proved to be safe for use with no real-time supervision of the sessions due to its security system. The device can be preconfigured to allow for an interval between sessions, duration of stimulation, intensity, maximum resistance, number of courses and active or sham stimulation predefined by a programmer. Therefore, it is possible to program for daily use of 20 min with a minimal interval of 12 hours between sessions (or other configurations). Thus, researchers can monitor adherence using information kept in the device software. Therefore, our results proved that device features ensure reliability and reproducibility of the stimulation, which is a crucial factor in the development of clinical trials.
Electrode-skin contact impedance is an important variable to ensure the safety of tDCS use 16, 21 . High impedance may be related to poor coupling between the electrode and the skin or dryness of the electrode's sponge. These situations may increase current density and lead to Copyright © 2018 Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License July 2018 | 137 | e57614 | Page 9 of 9 skin lesions 22 . In our study, the use of 6 mL of saline solution was sufficient to guarantee low contact impedance and was adequate and similar in both groups.
The adverse effects produced by our device do not differ from those reported in ambulatory use. Thus, our home-based tDCS resembles traditional equipment, and it is feasible, reliable and safe for use at home in consecutive sessions for long-term therapies, allowing the possibility of running more extensive clinical trials with larger samples.
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